Articles

Largest Peer-Reviewed Study on AI in Health Care Shows Real-World Significance of EyeArt AI Eye Screening System from Eyenuk

Landmark Study of Over 100,000 Diabetes Patient Visits Published in the Journal Diabetes Technology and Therapeutics Validates the Prowess of the EyeArt AI System for Diabetic Retinopathy Screening LOS ANGELES, August 08, 2019 –  Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye

Eyenuk’s AI Eye Screening System for Diabetic Retinopathy Demonstrates Exceptional Performance in a Prospective, Multi-Center, Pivotal Clinical Trial

LOS ANGELES, Calif., April 28, 2019 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results from its landmark prospective, multi-center, pivotal clinical trial to validate the EyeArt® AI Eye Screening System for autonomous detection of diabetic retinopathy (DR),

Artificial Intelligence helps identify Diabetic Retinopathy and Clinically Significant Diabetic Macular Edema

July 30, 2019. Chicago, IL: The results of a prospective study, titled “Artificial Intelligence Screening for Diabetic Retinopathy: Analysis from a Pivotal Multi-center Prospective Clinical Trial,” were presented at the 37TH American Society of Retina Specialists Annual Meeting by Jennifer Lim, MD (professor of ophthalmology and director of the Retina Service at University of Illinois

Researchers Study Improvement in Patient Compliance and Screening Efficacy by Using the EyeArt AI Eye Screening System for Detecting Diabetic Retinopathy

LOS ANGELES, June 5, 2019 – Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that data from scientific studies related to the screening efficacy of the EyeArt® AI Eye Screening System and the impact of using the EyeArt AI

German Diabetes Clinic Increases Diabetic Retinopathy Screenings Provided from Zero to Thousands After Implementing Eyenuk’s EyeArt AI Eye Screening System

LOS ANGELES, CA, May 16, 2019 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results of its expansion into Germany. Since adopting the EyeArt AI Eye Screening System in October 2018, Diabetes Center Mergentheim has screened thousands of

Eyenuk To Provide Artificial Intelligence (AI) Eye Screening to Thousands of Italians Through Collaboration With Ambrosian Ophthalmic Center in February

– 30 Centers Across Italy Will Provide AI Eye Screening for Diabetic Retinopathy, the Leading Cause of Vision Loss Among Working-age Adults – LOS ANGELES–Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that it is providing EyeArt® AI Eye